Business
Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 European Association of Urology Annual Congress
MIAMI, June 28, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the
About this update from Veru Inc.
[{"type":"text","content":"MIAMI, June 28, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancers, today announced updated clinical results from the ongoing Phase 1b/2 clinical study of sabizabulin (VERU-111), an oral cytoskeleton disruptor being evaluated for the treatment of metastatic castration resistant prostate cancer in men who progressed on an androgen receptor targeting agent, were accepted for presentation at the European Association of Urology 36th Annual Congress. The Congress is being held virtually from July 8-12, 2021. Poster Discussion SessionAbstract # P0859: Sabizabulin (VERU-111), an oral cytoskeleton disruptor, to treat men with metastatic castration resistant prostate cancer who progressed on an androgen receptor targeting agent.Presenter: Dr. Robert H. Getzenberg, Veru – Executive Vice President for Medical AffairsPoster Discussion Session: #29 – Metastatic Prostate CancerDate/Time: Sunday, July 11, 2021 4-5 PM CEST Additional information on the meeting can be found on the EAU website https://eaucongress.uroweb.org/ “The data from our Phase 1b/2 trial show that oral, daily sabizabulin is well tolerated and based upon its efficacy has the potential to fill the largest and growing unmet clinical need in men who have metastatic castration resistant prostate cancer and who have developed progression of prostate cancer while being treated with an androgen receptor targeting agent, but prior to using IV chemotherapy,” said Dr. Mitchell S. Steiner, Chairman, President and CEO of Veru Inc. “We are excited to be initiating the Phase 3 VERACITY trial in this patient population.” About Veru Inc.Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. Veru’s prostate cancer pipeline includes: sabizabulin, an oral, first-in-class, new chemical entity that targets the cytoskeleton disruptor which in prostate cancer also disrupts the transport of the androgen receptor. A Phase 3 VERACITY clinical trial evaluating the efficacy and safety of sabizabulin in approximately 245 men for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer is enrolling. VERU-100, a novel, proprietary gonado...